Some others, while in their early days, look to be on target, such as Merck's Victrelis, and Johnson & Johnson???s Zytiga while the jury is out on Benlysta, the lupus drug from Human Genome Sciences and GlaxoSmithKline, and Endo Pharmaceutical???s Fortesta.